Throughout the last three months, 7 analysts have evaluated Insmed (NASDAQ:INSM), offering a diverse set of opinions from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $89.71, a high estimate of $105.00, and a low estimate of $74.00. This upward trend is evident, with the current average reflecting a 5.54% increase from the previous average price target of $85.00.

Investigating Analyst Ratings: An Elaborate Study

A clear picture of Insmed's perception among...